Relmada Therapeutics
RLMD
44 hedge funds and large institutions have $15.5M invested in Relmada Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 8 closing their positions.
389% more capital invested
Capital invested by funds: $3.18M → $15.5M (+$12.4M)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
7.34% more ownership
Funds ownership: 15.98% → 23.32% (+7.3%)
12% less funds holding
Funds holding: 50 → 44 (-6)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.73M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$665K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$113K |
| 4 |
Two Sigma Investments
New York
|
+$75K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$69.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$116K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$78K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$35.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$27.6K |
| 5 |
Jane Street
New York
|
-$27.5K |
RLMD Hedge Fund Activity: Q3 2025 in Review
44 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2025, worth a combined $15.5M — up 389% from $3.18M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RLMD and 2 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 13 added.
The largest buyer was Ikarian Capital, adding an estimated $1.73M. The largest seller was UBS Group, cutting an estimated $116K.
- 44 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2025, down from 50 in Q2 2025.
- Funds reported $15.5M of Relmada Therapeutics stock for Q3 2025, up 389% quarter-over-quarter.
- 2 funds opened new Relmada Therapeutics positions in Q3 2025 and 8 closed out, a net change of -6 holders.
- The largest Relmada Therapeutics buyer in Q3 2025 was Ikarian Capital, an estimated $1.73M added.
- The largest Relmada Therapeutics seller in Q3 2025 was UBS Group, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2025.